View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
April 5, 2021updated 08 Apr 2021 10:05am

LoA Update: Relief’s aviptadil approvability score in Covid-19 rises by 11 points after positive Phase II/III results

Relief Therapeutics’ RLF-100 (aviptadil) received an 11-point boost in its likelihood of approval (LoA) as of 30 March, after the company announced a positive Phase II/III study in Covid-19.

Relief Therapeutics’ RLF -100 (aviptadil) received an 11-point boost in its likelihood of approval (LoA) as of 30 March, after the company announced a positive Phase II/III study in Covid-19.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Relief is developing aviptadil, a synthetic form of vasoactive intestinal peptide (VIP), in collaboration with Radnor, Pennsylvania-based NeuroRx. Relief will connect with European regulators once the full dataset is available and NeuroRx plans to apply for an Emergency Use Authorisation (EUA) based on these results, as per a 29 March press release. Additionally, a Phase II/III aviptadil study is scheduled to be initiated in Europe later this year.

The Phase II/III trial evaluated aviptadil’s efficacy in treating in critically ill Covid-19 patients and improved the recovery from respiratory failure—the trial’s primary outcome—at 28 days (p=0.014) and 60 days (p=0.013), as per the release. The F DA had specified the primary endpoint as recovery from respiratory failure, without relapse with discharge from acute care and survival through the observation period at 28 days, but as per recent guidance this was extended to 60 days. The trial enrolled 196 patients and had a randomised, double-blinded placebo-controlled design.

The LoA score, which is calculated by GlobalData’s analysis and uses a combination of machine learning and a proprietary algorithm, for aviptadil is now 43%, up from an initial 32%. An inhaled form of aviptadil is being tested in a Phase II/III study to treat moderate-to-severe Covid-19, while a yet-to-start investigator-led Phase I study to test this formulation as preventive measure is also listed on ClinicalTrials.gov.  NeuroRx is also working with the National Institutes of Health (NIH) for aviptadil’s inclusion in the adaptive Phase II I-SPY2 study for critically ill Covid-19 patients.

Relief’s market cap is $1bn (CHF 944.7m).

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena